FindTrial
Sign In

A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOVEAL AGE-RELATED MACULAR DEGENERATION (AMD)

A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOVEAL AGE-RELATED MACULAR DEGENERATION (AMD)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001301-10-IT
Enrollment
135
Registered
2005-03-15
Start date
2004-06-14
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AGE-RELATED MACULAR DEGENERATION MedDRA version: 6.1 Level: PT Classification code 10025409

Interventions

Product Name: pegaptanib sodium Pharmaceutical Form: Solution for injection INN or Proposed INN: pegaptanib sodium Concentration type: equal Concentration number: 0.3- Product Name: pegaptanib sodium

Sponsors

PFIZER
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026